BIDU Medical's trading volume on March 6 was $440 million, ranking 308th among U.S. stocks on that day.

robot
Abstract generation in progress

On March 6, 2026, medical device company Becton Dickinson (BDX) had a trading volume of $440 million, ranking 308th among U.S. stocks for the day, a decrease of 9.04% from yesterday, with a trading volume of 2.6334 million shares.

Becton Dickinson (BDX) fell 1.66% on March 6, 2026, to $167.12. The stock has declined 5.30% over the past five trading days, 5.30% for the entire March, down 13.89% year-to-date, and down 25.84% over the past 52 weeks.

If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to now (this also applies to listings less than 1 month or fewer than 5 trading days).

Becton Dickinson (BDX) Trading Volume / USD Change in Trading Volume from Yesterday Trading Volume
March 6, 2026 $440 million -9.04% 2.63M
March 5, 2026 $483 million 31.79% 2.86M
March 4, 2026 $367 million 0.15% 2.14M
March 3, 2026 $366 million -1.57% 2.11M
March 2, 2026 $372 million -54.39% 2.12M

Becton Dickinson released its Q1 FY2026 earnings report on February 9, 2026. Revenue from October 1, 2025, to December 31, 2025, was $5.25B, a year-over-year increase of 1.63%, with a net profit of $382 million, up 26.07% year-over-year.

Becton Dickinson Medical Devices Ltd. was incorporated in November 1906 under New Jersey law. The company is a global medical technology firm engaged in the development, manufacturing, and sale of various medical supplies, equipment, laboratory devices, and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the public. The company provides customer solutions focused on improving drug management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; assisting anesthesia care; enhancing infectious disease and cancer diagnostics; promoting cell research and applications; and supporting diabetes management.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin